

levodopa 20mg/mL + carbidopa monohydrate 5mg/mL + entacapone 20mg/mL intestinal gel (Lecigon®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2507	treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as not recommended for use in NHS Scotland	09/12/2024	20/11/2024
<b>Other Decision Specified :</b> The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8807/levodopa-carbidopa-entacapone-lecigon-final-jan-2023-amended-071124-for-website.pdf">https://scottishmedicines.org.uk/media/8807/levodopa-carbidopa-entacapone-lecigon-final-jan-2023-amended-071124-for-website.pdf</a>				
durvalumab (Imfinzi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2677	In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours $\geq$ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements.	Not routinely available as not recommended for use in NHS Scotland	09/12/2024	20/11/2024
<b>Other Decision Specified :</b> The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8810/durvalumab-imfinzi-final-nov-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8810/durvalumab-imfinzi-final-nov-2024-for-website.pdf</a>				

<b>zanubrutinib (Brukinsa®)</b>				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2684	as monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy	Available in line with local or regional guidance	09/12/2024	07/02/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8809/zanubrutinib-brukinsa-final-nov-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8809/zanubrutinib-brukinsa-final-nov-2024-for-website.pdf</a>				
<b>vibegron (Obgemsa®)</b>				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2696	symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/12/2024	07/02/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8808/vibegron-obgemsa-abb-final-nov-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8808/vibegron-obgemsa-abb-final-nov-2024-for-website.pdf</a>				